Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$50's?
I agree.
"Boiler room folks knew and intentionally kept it a secret"
Are you referring to the other investment site? Because the majority of us found out about the CH11 the day it was posted there.
And it's not as if it was insider information. It was public information that no one, except one or two, was aware of until posted.
He's stayed and has progressed upwards in his field over the years.
From intern, to technician, to engineer, supervisor and then manager.
He either knows what he is doing or is very lucky.
Pollyana?
What is this with regards to?
Is this with regards to the publication?
No, it is not.
I support the vast majority of vaccinations, including DC-Vax. I merely stated an observation and opinion regarding the covid vaccine specifically.
You assumed it was anti-vax.
It is ALSO ok to call into question a treatment/vaccination that may or may not be performing as promised.
Inflation is definitely higher than 8%
Wow, what a call.
I would assume they would apply for DC-Vax approval sometime soon. If it gets approved before manufacturing approval (or vice versa) it wouldn't matter.
The company states by end of year. I'm personally adding 3 months to that timeframe, as wrenches can sometimes be thrown into time tables.
I've worked in several manufacturing facilities, one being a clean room and another more industrial. I would argue that inspections and findings occur all the time, and TAKE time to resolve.
Regardless, I would personally be happy with a full manufacturing authorization by March of 2023.
I'm thinking he's waiting for something substantial to occur (partnership, deal, etc) before updating us.
But I doubt we'll get anything. Been 7 months since last PR. Willing to bet our next PR will be more fluff.
If they don't PR an actual deal that will provide immediate revenues, don't even bother.
With the OS at $15+ Billion, you'll need an insane reverse split.
Not sure if that $555 is a feasible number, but that'll be nice.
I believe they meant:
"Manufacturing will commence only after DC-Vax is approved".
So even if we get our manufacturing license, we'll still need regulatory approval for DC-Vax.
He was referring to UEEC on an possible FDA approval.
Not QMC. Completely different company.
Bid support is gone. Going to drop back to $0.6
:/
Seeing a lot of spam tweets about NWBO that directs to a discord chat room:
https://imgur.com/a/NQvsKEt
If you search on twitter for "$NWBO" you'll see what I mean.
Something coordinated planned?
Regardless, the point still stands.
Likewise Shoon's FUD train
Did he suggest this in order to burn shorts?
I don't think that's even possible with this share price.
We're already at over a billion shares with the PPS at $0.67
All I'm saying is that a 1 share sell is odd.
Somebody really needed that $0.65!
I figured some are trying to push the PPS down.
Unfortunately, it's been 3 years since then. If I am correct, QMC's PR's and filings regarding displays have been fairly scarce as of late.
One share was sold at 9:06am this morning.
Odd.
Is this new?
"GREEN-ROOM-TECHNOLOGIES-LLC-vs-STEPHEN-SQUIRES-QUANTUM-MATERIALS-CORP"
https://trellis.law/case/48453/D-1-GN-22-0023...RIALS-CORP
Filed, May 19th 2022.
Looks like Greenroom helped debut a PR for QMC back in 2019:
https://greenroomtx.com/quantum-materials-cor...lease-feb/
How so?
Hoping bear market conditions don't hamper NWBO's plans.
Slowly gaining traction within the community.
"Personalized cancer vaccine more then doubles survival in Glioblastoma, the deadliest brain cancer."
*By: Scott Zamore 6/10/2022
Scott Zamore appears to be a researcher/analyst for Chatham Asset Management, an $8 Billion Dollar Hedge Fund based in New Jersey
------
"The Dcvax fully personalized vaccine works by harnessing the bodies own immune system to fight the tumor. Surgeons take out as much tumor as possible along with a blood draw from the patient. The immune cells in the blood of the patient are then “taught” to fight the specific bio-markers found on the patients tumor. The vaccine is manufactured and then re-injected into the patient.
Biotech is a long & volatile road. Northwest Bio became highly distressed and almost faced bankruptcy as a result of their decision to extend and delay their lead Brain Cancer trial to completely capture the “long-tail” of survival they were seeing in many of their patients. The 80 oncologists in the trial started to see early on that many of their patients that had received the vaccine were living SIGNIFICANTLY longer then the normal 15-17 months that Glioblastoma patients live on chemotherapy + radiation.
To fully capture the survival figures of these patients within the data, the company chose to delay the Top-line data readout to get 5 year survival figures on all patients enrolled. Cancer patients are generally considered “cured” within the medical community when they live 5 years progression free after a treatment. When the oncologists in the trial saw some of their patients living 2-3 years past treatment early-on (which is already double+ the normal 15 month survival rate), they decided to delay the trial to see how many patients would be fully “cured” (5 Years survival).
Years of delays unfortunately within the pre-commercial biotech world= more dilution. Northwest burns around $2 million per month on staff and building out their world class manufacturing facility, and brings in very minimal revenue as their lead drug has just finished trials and has not yet gotten to market. Investors are on the hook for this $2mm/month, which led to a significant decline in the stock price given the constant financings.
Now that the data has been released, the tides are turning and the market has not yet fully taken notice. The medical community has come out with INCREDIBLE support for this data and the vaccine.
The Promising Innovative Medicines program in the UK, which this vaccine has the honor to be apart of (and the first ever drug approved for the program), just approved a $350 million fund to help patients pay for drugs within this program prior to full insurance reimbursement. This significantly decreases (if not fully eliminates) the cost to patients, and can start to bring in revenue for Northwest as the approval process plays out, reducing dilution on shareholders.
Unfortunately, the addressable market for glioblastoma is large (250k new cases diagnosed per year), but this represents a very large market opportunity, and Northwest has built out a massive manufacturing facility able to address this demand. Over 400 trials have failed to increase survival rates of glioblastoma patients since 2005, and this vaccine has finally moved the needle in a significant way and free of side-effects.
Their Phase 3 trial for Glioblastoma brain cancer showed highly statistically significant results in Newly Diagnosed GBM and Recurrent GBM (p values <.001, <.002) along with a significant long tail of survival (>228% increase in 5 year survival rate). The glioblastoma market is very large, and Dcvax is on its way to becoming the standard of care in this market. This alone represents a multi-billion market opportunity.
The even greater upside opportunity for this vaccine and company is that (1) this vaccine can also work on other solid tumor cancers- the company has increased patient survival rates in early stage trials on 15 other solid tumor cancers which represent 80% of the cancer market and (2) the vaccine can be used in combination with other pharma drugs and completely eliminate harsh/toxic chemotherapy and radiation. In early stage trials at UCLA using this vaccine in combo with Keytruda, they have managed to increase the 5 year survival rate in Glioblastoma to almost 50%- although this is some years away from entering into the market.
The Dcvax data from Northwest Bio represents years of hard work to reach significant scientific and technological advancement. The future is incredibly bright for cancer patients."
Full 25 minute Data Presentation-
He's referring to CYDY
My optimistic bias is telling me that them being swamped is a good thing.
Interesting!
Ding ding ding!
I see what you are saying.
This is probably due to the fact that the community is growing impatient waiting for the journal, coupled with the fear of "can the company still move forward without it?"
The community is in a tough/weird timeframe at the moment; Clinical information is out but no word on anything else from the company.
I think we'll be fine.
This is out of context.
He is saying one is not needed for the other to advance.
Need to use compound math
I understand, I'm just saying that TD shows post-market at .071
Trying to give you hope!
https://imgur.com/a/yfmNeyf
Last order was a "Buy" at $0.71
Order was executed at 16:00:16
16 seconds after close